Abstract:The stress-associated molecular chaperone system is an actionable target in cancer therapies. It is ubiquitously upregulated in cancer tissues and enables tumorigenicity by stabilizing hundreds of oncoproteins and disturbing the stoichiometry of protein complexes. Most inhibitors target the key component heat-shock protein 90 (HSP90). However, although classical HSP90 inhibitors are highly tumor-selective, they fail in phase 3 clinical oncology trials. These failures are at least partly due to an interference with a negative feedback loop by HSP90 inhibition, known as heat-shock response (HSR): in response to HSP90 inhibition there is compensatory synthesis of stress-inducible chaperones, mediated by the transcription factor heat-shock factor 1 (HSF1). We recently identified that wildtype p53 (p53) actively reduces the HSR by repressing HSF1 via a p21-CDK4/6-MAPK-HSF1 axis. Here we test the hypothesis that in HSP90-based therapies simultaneous p53 activation or direct cell cycle inhibition interrupts the deleterious HSF1-HSR axis and improves the efficiency of HSP90 inhibitors. Indeed, we find that the clinically relevant p53 activator Idasanutlin suppresses the HSF1-HSR activity in HSP90 inhibitor-based therapies. This combination synergistically reduces cell viability and accelerates cell death in p53-proficient colorectal cancer (CRC) cells, murine tumor-derived organoids and patient-derived organoids (PDOs). Mechanistically, upon combination therapy human CRC cells strongly upregulate p53-associated pathways, apoptosis, and inflammatory immune pathways. Likewise, in the chemical AOM/DSS CRC model in mice, dual HSF1-HSP90 inhibition strongly represses tumor growth and remodels immune cell composition, yet displays only minor toxicities in mice and normal mucosa-derived organoids. Importantly, inhibition of the cyclin dependent kinases 4 and 6 (CDK4/6) under HSP90 inhibition phenocopies synergistic repression of the HSR in p53-proficient CRC cells. Even more important, in p53-deficient (mutp53-harboring) CRC cells, an HSP90 inhibition in combination with CDK4/6 inhibitors similarly suppresses the HSF1-HSR system and reduces cancer growth. Likewise, p53-mutated PDOs strongly respond to dual HSF1-HSP90 pathway inhibition and thus, providing a strategy to target CRC independent of the p53 status. In sum, activating p53 (in p53-proficient cancer cells) or inhibiting CDK4/6 (independent of the p53 status) provide new options to improve the clinical outcome of HSP90-based therapies and to enhance colorectal cancer therapy.

Hsp90 chaperones wild-type p53 tumor suppressor protein

Hsp70 molecular chaperones are required to support p53 tumor suppressor activity under stress conditions

Hsp90β Interacts with MDM2 to Suppress P53‐dependent Senescence During Skeletal Muscle Regeneration

Chaperone-dependent stabilization and degradation of p53 mutants

Geldanamycin, a Heat Shock Protein 90‐binding Agent, Disrupts Stat5 Activation in IL‐2‐stimulated Cells

Inhibitors of the HSP90 Molecular Chaperone: Current Status

HSP90 and the chaperoning of cancer

Heat shock protein-90alpha (Hsp90α) stabilizes hypoxia-inducible factor-1α (HIF-1α) in support of spermatogenesis and tumorigenesis

P53 Regulates the Expression of Human Hsp90b Gene

Enhancement of colorectal cancer therapy through interruption of the HSF1-HSP90 axis by p53 activation or cell cycle inhibition

The co-chaperone p23 arrests the Hsp90 ATPase cycle to trap client proteins.

HSP90 as a new therapeutic target for cancer therapy: the story unfolds

Thr90 Phosphorylation of Hsp90α by Protein Kinase A Regulates Its Chaperone Machinery.

An alternatively spliced HDM2 product increases p53 activity by inhibiting HDM2

Effects of Wild-Type P53 Expression on the Quantity and Activity of Topoisomerase Ii Alpha and Beta in Various Human Cancer Cell Lines

Selective functional inhibition of a tumor-derived p53 mutant by cytosolic chaperones identified using split-YFP in budding yeast

A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors

Heat Shock Protein Gp96 Decreases P53 Stability by Regulating Mdm2 E3 Ligase Activity in Liver Cancer.

Therapeutic and diagnostic implications of Hsp90 activation

Stabilization of p53 by CP-31398 inhibits ubiquitination without altering phosphorylation at serine 15 or 20 or MDM2 binding.

HSP25 Down-Regulation Enhanced P53 Acetylation by Dissociation of SIRT1 from P53 in Doxorubicin-Induced H9c2 Cell Apoptosis